Evolving 5-fluorouracil therapy to achieve enhanced efficacy-past and current efforts of researchers

Yoshihiko Maehara, Eiji Oki, Hiroshi Saeki, Eriko Tokunaga, Hiroyuki Kitao, Makoto Iimori, Shinichiro Niimi, Yuki Kataoka, Yasunori Emi, Yoshihiro Kakeji, Hideo Baba, Tetsuhiko Shirasaka

Research output: Contribution to journalReview article

Abstract

5-fluorouracil (5-FU) therapy has advanced greatly over the past 50 years, achieving enhanced therapeutic effects and reduced adverse effects. By taking advantage of the metabolism of 5-FU, researchers have made efforts to develop prodrugs, combination drug products, and combination therapy regimens via biochemical modulation (BCM) with alteration of the drug metabolism. Examples include the advent of the prodrug tegafur (FT), followed by tegafur-uracil (UFT) and tegafurgimeracil-potassium oxonate (S-1) as combined products based on BCM. In the current standard treatment for gastrointestinal cancers, anticancer 5-FU derivatives serve as a platform for combination regimens with other cytotoxic agents or molecular-targeted drugs. To provide further improvements in anticancer therapy outcomes, novel molecular-targeted agents, immune checkpoint inhibitors, and other drugs are being developed, but 5-FU remains an attractive target that shows further potential for increased efficacy. In the future, the evolution of anticancer therapy with 5-FU derivatives is expected to continue via a variety of approaches.

Original languageEnglish
Pages (from-to)845-854
Number of pages10
JournalJapanese Journal of Cancer and Chemotherapy
Volume43
Issue number7
Publication statusPublished - Jul 2016

Fingerprint

Fluorouracil
Research Personnel
Tegafur
Prodrugs
Pharmaceutical Preparations
Therapeutics
Gastrointestinal Neoplasms
Uracil
Cytotoxins
Therapeutic Uses
Combination Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Evolving 5-fluorouracil therapy to achieve enhanced efficacy-past and current efforts of researchers. / Maehara, Yoshihiko; Oki, Eiji; Saeki, Hiroshi; Tokunaga, Eriko; Kitao, Hiroyuki; Iimori, Makoto; Niimi, Shinichiro; Kataoka, Yuki; Emi, Yasunori; Kakeji, Yoshihiro; Baba, Hideo; Shirasaka, Tetsuhiko.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 43, No. 7, 07.2016, p. 845-854.

Research output: Contribution to journalReview article

Maehara, Y, Oki, E, Saeki, H, Tokunaga, E, Kitao, H, Iimori, M, Niimi, S, Kataoka, Y, Emi, Y, Kakeji, Y, Baba, H & Shirasaka, T 2016, 'Evolving 5-fluorouracil therapy to achieve enhanced efficacy-past and current efforts of researchers', Japanese Journal of Cancer and Chemotherapy, vol. 43, no. 7, pp. 845-854.
Maehara, Yoshihiko ; Oki, Eiji ; Saeki, Hiroshi ; Tokunaga, Eriko ; Kitao, Hiroyuki ; Iimori, Makoto ; Niimi, Shinichiro ; Kataoka, Yuki ; Emi, Yasunori ; Kakeji, Yoshihiro ; Baba, Hideo ; Shirasaka, Tetsuhiko. / Evolving 5-fluorouracil therapy to achieve enhanced efficacy-past and current efforts of researchers. In: Japanese Journal of Cancer and Chemotherapy. 2016 ; Vol. 43, No. 7. pp. 845-854.
@article{9b1332941f9d42609a475f05784eb1fd,
title = "Evolving 5-fluorouracil therapy to achieve enhanced efficacy-past and current efforts of researchers",
abstract = "5-fluorouracil (5-FU) therapy has advanced greatly over the past 50 years, achieving enhanced therapeutic effects and reduced adverse effects. By taking advantage of the metabolism of 5-FU, researchers have made efforts to develop prodrugs, combination drug products, and combination therapy regimens via biochemical modulation (BCM) with alteration of the drug metabolism. Examples include the advent of the prodrug tegafur (FT), followed by tegafur-uracil (UFT) and tegafurgimeracil-potassium oxonate (S-1) as combined products based on BCM. In the current standard treatment for gastrointestinal cancers, anticancer 5-FU derivatives serve as a platform for combination regimens with other cytotoxic agents or molecular-targeted drugs. To provide further improvements in anticancer therapy outcomes, novel molecular-targeted agents, immune checkpoint inhibitors, and other drugs are being developed, but 5-FU remains an attractive target that shows further potential for increased efficacy. In the future, the evolution of anticancer therapy with 5-FU derivatives is expected to continue via a variety of approaches.",
author = "Yoshihiko Maehara and Eiji Oki and Hiroshi Saeki and Eriko Tokunaga and Hiroyuki Kitao and Makoto Iimori and Shinichiro Niimi and Yuki Kataoka and Yasunori Emi and Yoshihiro Kakeji and Hideo Baba and Tetsuhiko Shirasaka",
year = "2016",
month = "7",
language = "English",
volume = "43",
pages = "845--854",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - Evolving 5-fluorouracil therapy to achieve enhanced efficacy-past and current efforts of researchers

AU - Maehara, Yoshihiko

AU - Oki, Eiji

AU - Saeki, Hiroshi

AU - Tokunaga, Eriko

AU - Kitao, Hiroyuki

AU - Iimori, Makoto

AU - Niimi, Shinichiro

AU - Kataoka, Yuki

AU - Emi, Yasunori

AU - Kakeji, Yoshihiro

AU - Baba, Hideo

AU - Shirasaka, Tetsuhiko

PY - 2016/7

Y1 - 2016/7

N2 - 5-fluorouracil (5-FU) therapy has advanced greatly over the past 50 years, achieving enhanced therapeutic effects and reduced adverse effects. By taking advantage of the metabolism of 5-FU, researchers have made efforts to develop prodrugs, combination drug products, and combination therapy regimens via biochemical modulation (BCM) with alteration of the drug metabolism. Examples include the advent of the prodrug tegafur (FT), followed by tegafur-uracil (UFT) and tegafurgimeracil-potassium oxonate (S-1) as combined products based on BCM. In the current standard treatment for gastrointestinal cancers, anticancer 5-FU derivatives serve as a platform for combination regimens with other cytotoxic agents or molecular-targeted drugs. To provide further improvements in anticancer therapy outcomes, novel molecular-targeted agents, immune checkpoint inhibitors, and other drugs are being developed, but 5-FU remains an attractive target that shows further potential for increased efficacy. In the future, the evolution of anticancer therapy with 5-FU derivatives is expected to continue via a variety of approaches.

AB - 5-fluorouracil (5-FU) therapy has advanced greatly over the past 50 years, achieving enhanced therapeutic effects and reduced adverse effects. By taking advantage of the metabolism of 5-FU, researchers have made efforts to develop prodrugs, combination drug products, and combination therapy regimens via biochemical modulation (BCM) with alteration of the drug metabolism. Examples include the advent of the prodrug tegafur (FT), followed by tegafur-uracil (UFT) and tegafurgimeracil-potassium oxonate (S-1) as combined products based on BCM. In the current standard treatment for gastrointestinal cancers, anticancer 5-FU derivatives serve as a platform for combination regimens with other cytotoxic agents or molecular-targeted drugs. To provide further improvements in anticancer therapy outcomes, novel molecular-targeted agents, immune checkpoint inhibitors, and other drugs are being developed, but 5-FU remains an attractive target that shows further potential for increased efficacy. In the future, the evolution of anticancer therapy with 5-FU derivatives is expected to continue via a variety of approaches.

UR - http://www.scopus.com/inward/record.url?scp=84991451240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991451240&partnerID=8YFLogxK

M3 - Review article

C2 - 27431628

AN - SCOPUS:84991451240

VL - 43

SP - 845

EP - 854

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -